Month: October 2015

The evidence for low vitamin D levels being a risk factor for development of MS is becoming more compelling. In fact, some studies have shown that low vitamin D early in the disease course predicted worse MS clinical and MRI activity and disease progression. A new study sheds light as to why this might be…. Read more »

There are now 11 medications, FDA approved, for relapsing and remitting MS. Other than Novantrone, which is no longer used because of safety issues that were worse than initially predicted, no medication has been approved for progressive MS. The current thrust of research is neuroprotection rather than anti-inflammatory effects. Below is the summary of studies… Read more »